Abstract
The entorhinal cortex is one of the first regions to exhibit neurodegeneration in Alzheimer’s disease, and as such identification of entorhinal cortex dysfunction may aid detection of the disease in its earliest stages. Extensive evidence demonstrates that the entorhinal cortex is critically implicated in navigation underpinned by the firing of spatially modulated neurons. This study tested the hypothesis that entorhinal-dependent navigation is impaired in pre-dementia Alzheimer’s disease.
Forty-five patients with mild cognitive impairment (26 with CSF Alzheimer’s disease biomarker data: 12 biomarker-positive and 14 biomarker-negative) and 41 healthy control participants undertook an immersive virtual reality path integration test, as a measure of entorhinal-dependent navigation. Behavioural performance was correlated with MRI measures of entorhinal cortex volume, and the classification accuracy of the path integration task was compared with a battery of cognitive tests considered sensitive and specific for early Alzheimer’s Disease.
Biomarker-positive patients exhibited larger errors in the navigation task than biomarker-negative patients, whose performance did not significantly differ from controls participants. Path-integration errors were negatively correlated with the volumes of the total entorhinal cortex and of its posteromedial subdivision. The path integration task demonstrated higher diagnostic sensitivity and specificity for differentiating biomarker positive versus negative patients (area under the curve = 0.90) than was achieved by the best of the cognitive tests (area under the curve = 0.57).
This study demonstrates that an entorhinal cortex-based virtual reality navigation task can differentiate patients with mild cognitive impairment at low and high risk of developing dementia, with classification accuracy superior to reference cognitive tests considered to be highly sensitive to early Alzheimer’s disease. This study provides evidence that navigation tasks may aid early diagnosis of Alzheimer’s disease, and the basis of this in animal cellular and behavioural studies provides the opportunity to answer the unmet need for translatable outcome measures for comparing treatment effect across preclinical and clinical trial phases of future anti-Alzheimer’s drugs.
- Abbreviations
- 4MT
- Four Mountains Task
- ACE-R
- Addenbrookes Cognitive Examination – Revised
- alEC
- anterior-lateral Entorhinal Cortex
- AUC
- Area Under the Curve
- CDR
- Clinical Dementia Rating
- EC
- Entorhinal Cortex
- DST
- Digit Symbol Substitution Test
- FCSRT
- Free and Cued Selective Remind Test
- HCs
- Healthy Controls
- iVR
- immersive Virtual Reality
- lEC
- lateral Entorhinal Cortex
- LME
- Linear Mixed Effect Model
- MCI
- Mild Cognitive Impairment
- MCI+
- Mild Cognitive Impairment with CSF evidence of underlying Alzheimer’s Disease.
- MCI−
- Mild Cognitive Impairment without CSF evidence of underlying Alzheimer’s Disease.
- mEC
- medial Entorhinal Cortex
- MMSE
- Mini-Mental State Examination
- NART
- National Adult Reading Test
- PCC
- Posterior Cingulate Cortex
- PI
- Path Integration
- pmEC
- posterior-medial Entorhinal Cortex
- RSc
- RetroSplenial cortex
- RFR
- Rey-Osterrieth Figure Recall Test
- ROC
- Receiver Operating Characteristic
- ROI
- Region of Interest
- TMTB
- Trail Making Test B